To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study / Baeten, Dominique; Østergaard, Mikkel; Wei, James Cheng-Chung; Sieper, Joachim; Järvinen, Pentti; Tam, Lai-Shan; Salvarani, Carlo; Kim, Tae-Hwan; Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; Hall, David B; Aslanyan, Stella; Scholl, Paul; Padula, Steven J. - In: EARD. - ISSN 1468-2060. - 77:9(2018), pp. 1295-1302. [10.1136/annrheumdis-2018-213328]

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Salvarani, Carlo;
2018

Abstract

To evaluate the efficacy and safety of risankizumab, a humanised monoclonal antibody targeting the p19 subunit of interleukin-23 (IL-23), in patients with active ankylosing spondylitis (AS).
26-giu-2018
77
9
1295
1302
Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study / Baeten, Dominique; Østergaard, Mikkel; Wei, James Cheng-Chung; Sieper, Joachim; Järvinen, Pentti; Tam, Lai-Shan; Salvarani, Carlo; Kim, Tae-Hwan; Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; Hall, David B; Aslanyan, Stella; Scholl, Paul; Padula, Steven J. - In: EARD. - ISSN 1468-2060. - 77:9(2018), pp. 1295-1302. [10.1136/annrheumdis-2018-213328]
Baeten, Dominique; Østergaard, Mikkel; Wei, James Cheng-Chung; Sieper, Joachim; Järvinen, Pentti; Tam, Lai-Shan; Salvarani, Carlo; Kim, Tae-Hwan; Solinger, Alan; Datsenko, Yakov; Pamulapati, Chandrasena; Visvanathan, Sudha; Hall, David B; Aslanyan, Stella; Scholl, Paul; Padula, Steven J
File in questo prodotto:
File Dimensione Formato  
1295.full.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 1.3 MB
Formato Adobe PDF
1.3 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1167263
Citazioni
  • ???jsp.display-item.citation.pmc??? 85
  • Scopus 204
  • ???jsp.display-item.citation.isi??? 187
social impact